Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported quarterly earnings of $0.17 per share which missed the analyst consensus estimate of $0.38 by 54.67 percent. This is a 241.67 percent increase over losses of $(0.12) per share from the same period last year. The company reported quarterly sales of $202.127 million which beat the analyst consensus estimate of $195.005 million by 3.65 percent. This is a 64.95 percent increase over sales of $122.536 million the same period last year.